Head to head comparison of adverse effects and efficacy between high dose deflazacort and high dose prednisolone in systemic lupus erythematosus: a prospective cohort study

Abstract

Background

Deflazacort (DFZ), an oxazoline derivative of prednisolone (PDN), has a dose equivalence of 1.2:1 (mg) to PDN. No study to date has compared adverse effects and efficacy of high doses of DFZ as against high-dose PDN in systemic lupus erythematosus (SLE).

Objectives

To compare adverse effects of high dose DFZ and PDN in SLE patients, especially in terms of cushingoid features and gain in body weight, 3 and 6 months after initiation of these agents.

Methods

In both the steroid arms, the following outcome parameters were assessed at 3 and 6 months: (a) cushingoid features by Cushing's Severity Index (CSI) (b) hirsutism by modified Ferriman Gallwey score (c) weight gain by difference (Δ, delta) of weight (in kilograms).

Results

Patients on PDN had 1.6 kg (3.2%) and 2 kg (5.1%) higher median weight gain as compared to those on DFZ at 3 and 6 months respectively ( p = 0.012 and 0.001). PDN caused 10% and 22.2% higher increment in median hirsutism scores as compared to DFZ at 3 months and 6 months follow-up, respectively ( p = 0.004 and 0.002). PDN caused 100% higher increase in median CSI scores than DFZ at 6 months ( p = 0.03). There was no significant difference by generalized estimation equation between the groups with respect to changes in SLEDAI, renal SLEDAI, anti-dsDNA titres and C3/C4 levels. There were two serious infections (requiring hospitalization/intravenous antibiotics) in the PDN group, while none in the DFZ group.

Conclusion

Comparable intake and tapering of high dose DFZ and PDN in active SLE revealed 2-fold less weight gain, 2.5-fold less hirsutism and 1.5-fold lower cushingoid severity index as well as lower glycaemic elevation in the DFZ group as compared to PDN group. Both had similar efficacy.

Keywords

Adverse effects deflazacort efficacy prednisolone systemic lupus erythematosus steroids

Get full access to this article

View all access options for this article.

References

Krogsgaard

Lund

Johnsson

. A long-term prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica. J Rheumatol 1995; 22: 1660–1662.

Avioli

. Potency ratio: a brief synopsis. Br J Rheumatol 1993; 32(Suppl 2): 24–26.

Montecucco

Baldi

Fortina

et al.

Serum osteocalcin (bone Gla-protein) following corticosteroid therapy in postmenopausal women with rheumatoid arthritis. Comparison of the effect of prednisone and deflazacort. Clin Rheumatol 1988; 7: 366–371.

Olgaard

Storm

van Wowern

et al.

Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort. Calcif Tissue Int 1992; 50: 490–497.

Möllmann

Hochhaus

Rohatagi

Barth

Derendorf

. Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharm Res 1995; 12: 1096–1100.

Gennari

. Differential effect of glucocorticoids on calcium absorption and bone mass. Br J Rheumatol 1993; 32(Suppl 2): 11–14.

Bruno

. Deflazacort vs prednisone: effect on blood glucose control in insulin-treated diabetics. Arch Intern Med 1987; 147: 679.

Karimzadeh

Ghazavi

. Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. IJCN 2012; 6: 5–12.

Bombardier

Gladman

Urowitz

Caron

Chang

. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–640.

10.

Scudeletti

Puppo

Lanza

et al.

Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases. Eur J Clin Pharmacol 1993; 45: S29–S34.

11.

Markham

Bryson

. Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Drugs 1995; 50: 317–333.

12.

Sonino

Boscaro

Fallo

Fava

. A clinical index for rating severity in Cushing's syndrome. Psychother Psychosom 2000; 69: 216–220.

13.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

14.

Petri

Orbai

A-M

Alarcón

et al.

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

15.

WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157–163.

16.

Miloslavsky

Naden

Bijlsma

JWJ

Brogan

Brown

Brunetta

et al.

Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017; 76(3): 543–546.

17.

Griggs

Miller

Greenberg

et al.

Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology 2016; 87: 2123–2131.

18.

Coirini

Flores

Vega

Gonzalez Deniselle

De Nicola

. Binding of the anti-inflammatory steroid deflazacort to glucocorticoid receptors in brain and peripheral tissues. In vivo and in vitro studies. J Steroid Biochem Mol Biol 1994; 49: 43–49.

19.

Assandri

Buniva

Martinelli

Perazzi

Zerilli

. Pharmacokinetics and metabolism of deflazacort in the rat, dog, monkey and man. Adv Exp Med Biol 1984; 171: 9–23.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.44 MB